IRIDEX (NASDAQ:IRIX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a report released on Wednesday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Down 1.8 %

NASDAQ IRIX opened at $1.61 on Wednesday. The stock has a fifty day moving average of $1.70 and a 200-day moving average of $1.76. IRIDEX has a 52 week low of $1.27 and a 52 week high of $3.65. The stock has a market capitalization of $26.79 million, a P/E ratio of -2.40 and a beta of 0.84. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. The company had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same period in the previous year, the firm posted ($0.11) earnings per share.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.